RE:3 scenarios by the end of Sept Distribution deal should be a guarantee unless there worried about COVID-19 recurring in which case they may prolong it further. Trulance should have been wrapped up last month the arbitrator must be mulling final ruling and payment. Not sure of the 3 dollar guess but 2 should be doable by year end. Look for new analyst earnings and revenue if no generics move in to compete with Absorica. Next year Trevyent should be ready for another run at the FDA.